Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of circular RNA medicines and unprecedented lipid nanoparticle (LNP) delivery solutions for oncology and ...

The Killing Sense is set in Paris. At its centre is Galway-born, London-based single mother Kate Wilde, who has managed to ...

Kailera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of ...

MPM BioImpact, a biotechnology investment firm creating and investing in innovative companies seeking to deliver ...

Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.

About four years after launch, Orna Therapeutics Inc. signed its second major deal, this time validating the lipid nanoparticle delivery technology it acquired through its Renagade Therapeutics Inc.

Vertex Pharmaceuticals Inc. will work with a Watertown biotech on new gene-editing therapies for people with sickle cell ...

Four judges with different backgrounds explain their methods for picking winning entries at the Pennsylvania Farm Show.

Orna Therapeutics, through its subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with Vertex ...

Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...

TCS, Tata Elxsi, Reliance Home Finance, One Mobikwik Systems, DMart (Avenue Supermart), and IREDA are some of the major firms ...